ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
22 hedge funds and large institutions have $16.1M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 2 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
2.12% more ownership
Funds ownership: 33.82% → 35.94% (+2.1%)
0% more capital invested
Capital invested by funds: $16.1M → $16.1M (+$32.1K)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.1M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$349K |
| 3 |
Jane Street
New York
|
+$230K |
| 4 |
LWPC
Legacy Wealth Partners (California)
Calabasas,
California
|
+$164K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
-$876K |
| 2 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$55K |
| 3 |
PWM
Perigon Wealth Management
San Francisco,
California
|
-$32K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$26K |
| 5 |
LPL Financial
San Diego,
California
|
-$25.5K |
CNCR Hedge Fund Activity: Q1 2021 in Review
22 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q1 2021, worth a combined $16.1M — up 0.2% from $16.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CNCR positions and 2 closed out — a net gain of 2 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $1.1M. The largest seller was BCWM LLC, cutting an estimated $876K.
- 22 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $16.1M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q1 2021, up 0.2% quarter-over-quarter.
- 4 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q1 2021 and 2 closed out, a net change of +2 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q1 2021 was Citadel Advisors, an estimated $1.1M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q1 2021 was BCWM LLC, an estimated $876K sold.
Based on aggregated 13F filings for Q1 2021.